Dermatology Advisor

Denifanstat May Improve Lesion Count in Moderate to Severe Acne Vulgaris

Early results from a phase 2 clinical trial show that denifanstat for 12 weeks improved lesion counts in patients with acne vulgaris.
Healio

1,726 nm laser effective in treating acne vulgaris

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A multi-center, prospective, open-label, single arm ...
Healio

M-PDT efficacy similar to isotretinoin in acne vulgaris

Please provide your email address to receive an email when new articles are posted on . M-PDT showed similar efficacy rates compared with isotretinoin with fewer adverse events. A faster onset of ...

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) ...

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market

Sagimet Biosciences Inc. stock rated Strong Buy on promising drug data and pipeline growth in acne and MASH. Click for this ...
Business Insider

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...
Business Insider

Dermata Therapeutics Announces Completion of Enrollment in a Phase 2b Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris

SAN DIEGO, Feb. 11, 2020 /PRNewswire/ -- Dermata Therapeutics, LLC, a privately held biotechnology company, announced today that it has completed enrollment of patients in its Phase 2b clinical trial ...
Nasdaq

Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris

The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the end of this year BRIDGEWATER, N.J., June 02, 2020 (GLOBE ...
Business Wire

Almirall PROSES study demonstrates appropriate acne treatment decreases the burden of impact on acne sufferers’ social and emotional wellbeing

MALVERN, Pa.--(BUSINESS WIRE)--Almirall, LLC, a global biopharmaceutical company focused on skin health, is excited to announce the release of its privately funded PROSES study at this year’s Fall ...
Monthly Prescribing Reference

Amzeeq Now Available for Moderate to Severe Acne

Amzeeq topical foam 4% will soon be available (January 13, 2020) by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and ...
Nasdaq

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical ...

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received ...